Search

… Job Title Assistant Attending Degree MD, PhD

Alyona Weinstein is a family nurse practitioner (NP) on the Integrative Medicine and Wellness Service.

… Job Title Nurse Practitioner I am a family nurse practitioner (NP) on the Integrative Medicine and Wellness Service , where I work with patients with various types of cancer, as well as patients who have survived cancer. My career at Memorial Sloan Kettering Cancer Center (MSK) began in 2012, when I

Collaboration is key to everything we do, and we’re dedicated to making our ties with our healthcare professionals even stronger.

… In partnership with you — the medical student, oncology fellow, nurse, physician, technician, or other professional in training or practice  — we’re discovering more about the pathogenesis of cancer and allied diseases every day, finding better treatment options and cures for people with all forms of

… Job Title Research Technician

… Job Title Research Fellow The identification of novel prostate cancer therapeutics is a significant clinical need because current hormone therapies eventually fail, leading to a drug-resistant and fatal disease termed castrate-resistant prostate cancer. Men with castrate-resistant prostate cancer often

… Job Title Administrative Coordinator Education MS, Stony Brook University Degree MS Mentor Edit Biro, HHMI Email [email protected] Office Fax 646-888-3347 Office Phone 646-888-3343

MSK music therapist Holly Mentzer shares a song and explains how listening to or writing music can help regulate your feelings.

… MSK music therapist Holly Mentzer shares a song and explains how listening to or writing music can help regulate your feelings. Hi, my name is Holly Mentzer.  I’m a board-certified Music Therapist at MSK.  And I’m here today to share a song I wrote about anger.  Anger is a really strong feeling of being

"When the weather's still nice and I can get out while it's light out, I like to bring my dog to Central Park and let her run around," Caroline says.

… “When the weather’s still nice and I can get out while it’s light out, I like to bring my dog to Central Park and let her run around,” Caroline says.

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

… Wednesday, October 2, 2019 Bottom Line: Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman

Please watch before submitting a volunteer application.